ANSWER: Heart failure is simply when the heart is unable to pump all the blood it needs to meet the body’s demands. Heart ...
Several epidemiological studies confirm that the prevalence of heart failure with normal ejection fraction is increasing. Given the current trends, heart failure with normal ejection fraction will ...
Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR), according to a study ...
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major health concern. Pathological stimuli and interactions between cardiac fibroblasts (CFs) and other cell types may lead to ...
In 2022, empagliflozin (Jardiance) was approved for a broader indication in heart failure across the spectrum of ejection fraction (EF). In 2023, another SGLT2 inhibitor, dapagliflozin (Farxiga ...